AT1 receptor antagonism is proangiogenic in the brain: Bdnf a novel mediators

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 2, 2013, Pages 348-359

  Alhusban, Ahmed ^a   Kozak, Anna ^a   Ergul, Adviye ^a,b   Fagan, Susan C ^a,b  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BRAIN DERIVED NEUROTROPHIC FACTOR; CANDESARTAN; HYDRALAZINE; PLACEBO; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; BRAIN TISSUE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG TARGETING; HYPERTENSION; MALE; MICROVASCULAR ENDOTHELIAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STUDY; RAT; RECEPTOR BLOCKING; UPREGULATION; ANIMAL; BIOSYNTHESIS; BRAIN; CELL CULTURE; CELL MOTION; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; METABOLISM; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULARIZATION; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BLOTTING, WESTERN; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; HYPERTENSION; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, INBRED SHR; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES;

MLCS; MLOWN;

EID: 84872693831     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.197483     Document Type: Article

References (45)

1. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, and Wedel H; LIFE Study Group. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1002.
2. Buharalioglu CK, Song CY, Yaghini FA, Ghafoor HU, Motiwala M, Adris T, Estes AM, and Malik KU (2011) Angiotensin II-induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor-1 phosphorylation. Am J Physiol Heart Circ Physiol 301:H1043-H1055.
3. Caporali A and Emanueli C (2009) Cardiovascular actions of neurotrophins. Physiol Rev 89:279-3078.
4. Chan SH, Wu CW, Chang AY, Hsu KS, and Chan JY (2010) Transcriptional upregulation of brain-derived neurotrophic factor in rostral ventrolateral medulla by angiotensin II: significance in superoxide homeostasis and neural regulation of arterial pressure. Circ Res 107:1127-1139.
5. De Paolis P, Porcellini A, Gigante B, Giliberti R, Lombardi A, Savoia C, Rubattu S, and Volpe M (1999) Modulation of the AT2 subtype receptor gene activation and expression by the AT1 receptor in endothelial cells. J Hypertens 17: 1873-1877. (Pubitemid 30345325)
6. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, and Schulz R (2004) The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 24:467-474. (Pubitemid 38455442)
7. Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, Ergul A, and Hess DC (2006) Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens 24:535-539. (Pubitemid 43261918)
8. Faure S, Bureau A, Oudart N, Javellaud J, Fournier A, and Achard JM (2008) Protective effect of candesartan in experimental ischemic stroke in the rat mediated by AT2 and AT4 receptors. J Hypertens 26:2008-2015.
9. Feletou M (2011) Series on Integrated Systems Physiology: From Molecule to Function to Disease, in The Endothelium: Part 1: Multiple Functions of the Endothelial Cells - Focus on Endothelium-Derived Vasoactive Mediators (Granger DNGJ, ed) Morgan & Claypool Life Sciences, San Rafael, CA.
10. Flügel D, Görlach A, and Kietzmann T (2012) GSK-3b regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1a. Blood 119:1292-1301.
11. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y, Masaki H, Uchiyama Y, Koyama Y, and Nose A, et al. (2001) Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation. Circ Res 88:22-29. (Pubitemid 32064078)
12. Greenberg ME, Xu B, Lu B, and Hempstead BL (2009) New insights in the biology of BDNF synthesis and release: implications in CNS function. J Neurosci 29: 12764-12767.
13. Guan W, Somanath PR, Kozak A, Goc A, El-Remessy AB, Ergul A, Johnson MH, Alhusban A, Soliman S, and Fagan SC (2011) Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. PLoS ONE 6:e24551.
14. Hashikawa-Hobara N, Hashikawa N, Inoue Y, Sanda H, Zamami Y, Takatori S, and Kawasaki H (2012) Candesartan cilexetil improves angiotensin II type 2 receptor-mediated neurite outgrowth via the PI3K-Akt pathway in fructoseinduced insulin-resistant rats. Diabetes 61:925-932.
15. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, and Wulff C (2008) Regulation of endothelial proliferation by the renin-angiotensin system in human umbilical vein endothelial cells. Reproduction 136:125-130. (Pubitemid 351984726)
16. Hu C, Dandapat A, and Mehta JL (2007) Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension 50:952-957. (Pubitemid 350287540)
17. Hur EM and Zhou FQ (2010) GSK3 signalling in neural development. Nat Rev Neurosci 11:539-551.
18. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, Sakanaka M, Shiuchi T, and Horiuchi M (2004) Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110:843-8478.
19. Carbajo-Lozoya J, Lutz S, Feng Y, Kroll J, Hammes HP, and Wieland T (2012) Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium. Cell Signal 24: 1261-1269.
20. Kou B, Vatish M, and Singer DR (2007) Effects of angiotensin II on human endothelial cells survival signalling pathways and its angiogenic response. Vascul Pharmacol 47:199-2078.
21. Kozak A, Ergul A, El-Remessy AB, Johnson MH, Machado LS, Elewa HF, Abdelsaid M, Wiley DC, and Fagan SC (2009) Candesartan augments ischemia-induced proangiogenic state and results in sustained improvement after stroke. Stroke 40: 1870-1876.
22. Kozak W, Kozak A, Johnson MH, Elewa HF, and Fagan SC (2008) Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. J Pharmacol Exp Ther 326:773-782.
23. Li J, Culman J, Hörtnagl H, Zhao Y, Gerova N, Timm M, Blume A, Zimmermann M, Seidel K, and Dirnagl U, et al. (2005) Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 19:617-619. (Pubitemid 40471263)
24. Li Q, Ford MC, Lavik EB, and Madri JA (2006) Modeling the neurovascular niche: VEGF- and BDNF-mediated cross-talk between neural stem cells and endothelial cells: an in vitro study. J Neurosci Res 84:1656-16678.
25. Li Q, Michaud M, Canosa S, Kuo A, and Madri JA (2011) GSK-3b: a signaling pathway node modulating neural stem cell and endothelial cell interactions. Angiogenesis 14:173-185.
26. Lu Q, Zhu YZ, and Wong PT (2005) Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport 16:1963-1967. (Pubitemid 41653523)
27. Madri JA (2009) Modeling the neurovascular niche: implications for recovery from CNS injury. J Physiol Pharmacol 60 (Suppl 4):95-104.
28. McCarthy CA, Vinh A, Callaway JK, and Widdop RE (2009) Angiotensin AT2 receptor stimulation causes neuroprotection in a conscious rat model of stroke. Stroke 40:1482-1489.
29. Miura S, Matsuo Y, Kiya Y, Karnik SS, and Saku K (2010) Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors. Biochem Biophys Res Commun 391:85-90.
30. Munk VC, Sanchez de Miguel L, Petrimpol M, Butz N, Banfi A, Eriksson U, Hein L, Humar R, and Battegay EJ (2007) Angiotensin II induces angiogenesis in the hypoxic adult mouse heart in vitro through an AT2-B2 receptor pathway. Hypertension 49:1178-1185. (Pubitemid 351664302)
31. Navaratna D, Guo S, Arai K, and Lo EH (2009) Mechanisms and targets for angiogenic therapy after stroke. Cell Adhes Migr 3:216-223.
32. Oprisiu-Fournier RFS,Mazouz H, Boutitie F, Serot JM, Achard JM, Godefroy O, Hanon O, Temmar M, Albu A, and Strandgaard S, et al. (2009) Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors? Expert Rev Neurother9:1289-1305.
33. Otani A, Takagi H, Suzuma K, and Honda Y (1998) Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 82:619-6278.
34. Parrish JZ, Emoto K, Kim MD, and Jan YN (2007) Mechanisms that regulate establishment, maintenance, and remodeling of dendritic fields. Annu Rev Neurosci 30:399-423. (Pubitemid 47218762)
35. Saavedra JM (1999) Emerging features of brain angiotensin receptors. Regul Pept 85: 31-45. (Pubitemid 29505283)
36. Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, and Wilkinson-Berka JL (2003) Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol 163:879-887. (Pubitemid 37040124)
37. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, and Drexler H (1994) Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89:2273-2282. (Pubitemid 24142808)
38. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, and Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group (2003) The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 34:1699-1703. (Pubitemid 36842630)
39. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, and Diener HC; MOSES Study Group (2005) Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36: 1218-1226.
40. Schulz M and Schmoldt A (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447-474. (Pubitemid 36869876)
41. Sladek T, Sladkova J, Kolar F, Papousek F, Cicutti N, Korecky B, and Rakusan K (1996) The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res 31:568-576. (Pubitemid 26140064)
42. Szekeres M, Nádasy GL, Turu G, Süpeki K, Szidonya L, Buday L, Chaplin T, Clark AJ, and Hunyady L (2010) Angiotensin II-induced expression of brain-derived neurotrophic factor in human and rat adrenocortical cells. Endocrinology 151: 1695-1703.
43. Wada A (2009) Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci 110:14-278.
44. Willis LM, El-Remessy AB, Somanath PR, Deremer DL, and Fagan SC (2011) Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci (Lond) 120:307-319.
45. Xiong Y, Mahmood A, and Chopp M (2010) Angiogenesis, neurogenesis and brain recovery of function following injury. Curr Opin Investig Drugs 11:298-3078.